Urology and Uro-Oncology


Helping patients with urologic cancer

Developing life-changing therapies for unmet medical needs

Urology and Uro-Oncology

In a single year, the number of Americans newly diagnosed with bladder cancer is estimated to be about 82,000.1

More than half of the patients diagnosed with high-risk non-muscle invasive bladder cancer (NMIBC) who receive initial treatment with the intravesical immunotherapy Bacillus Calmette-Guérin (BCG) will experience disease recurrence and progression within one year, with many developing BCG-unresponsive disease.2

Most patients need additional treatment options after BCG, but few options are available for adult patients with high-risk NMIBC following BCG treatment who have persistent or recurrent disease.3,4,5,

Ferring develops life-changing therapies to address the unmet medical needs of patients diagnosed with bladder and other urological cancers.


  1. American Cancer Society. Key statistics for bladder cancer. Accessed May 8, 2023. https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html 
  2. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021; 22:107–17.
  3. Di Lorenzo G, et al. Cancer 2010;116:1893–1900.
  4. Goossens-Laan CA, et al. Support Care Cancer 2014;22:189–200.
  5. Winters BR, et al. J Urol 2018;199:669–675.

Discover Project Family